Telisotuzumab Vedotin
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 29, 2026
Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.
Journal: Thoracic research and practice
Published: December 29, 2025
An overview of recent advancements in targeted cancer therapies and their potential clinical impact.
An overview of recent advancements in targeted cancer therapies and their potential clinical impact.
Journal: RSC medicinal chemistry
Published: August 23, 2025
Telisotuzumab vedotin (Emrelis) for non-small cell lung cancer.
Journal: The Medical letter on drugs and therapeutics
Published: July 29, 2025
Evaluating the combined efficacy of Telisotuzumab Vedotin and artificial intelligence in the treatment of non-squamous non-small cell lung cancer: a narrative review focusing on pharmaceutical and technical insights.
Journal: Frontiers in oncology
Published: July 26, 2025
Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC).
Journal: Drug discoveries & therapeutics
Published: July 13, 2025
Emrelis (telisotuzumab vedotin-tllv): targeting C-MET in non-small cell lung cancer.
Journal: Annals of medicine and surgery (2012)
Published: June 22, 2025
Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically-Based Pharmacokinetic Modeling and Simulations.
Journal: Journal of clinical pharmacology
Published: June 18, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Journal: Nature reviews. Clinical oncology
Published: June 12, 2025
Last Updated: 04/28/2026